Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,290 across all filing types
Latest filing 2021-04-16 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物关于召开2020年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about a 2020 annual performance explanation meeting (业绩说明会) to be held on April 27, 2021. It mentions the upcoming disclosure of the 2020 annual report on the Shanghai Stock Exchange website but does not contain the report itself or detailed financial data. The document invites investors to participate in a Q&A session regarding the 2020 annual results. The length is short (1328 characters), and it serves as a notice for an investor presentation event rather than the report or transcript itself. Therefore, it fits best as an Investor Presentation (IP) announcement.
2021-04-16 Chinese
关于出售参股公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the sale of equity in an associate company, Mobidiag Oy, to Hologic, Inc. It details the transaction overview, parties involved, financial data of the target and buyer, contract terms, and impact on the company. The document is an official announcement of a capital transaction involving share disposal, not a financial report or earnings release. It does not contain comprehensive financial statements or management discussion but focuses on the sale of shares and related corporate information. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3221 characters, which is consistent with an announcement rather than a full report.
2021-04-08 Chinese
关于公司第三届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Zhengzhou Antu Bioengineering Co., Ltd. regarding a specific board meeting agenda item about the sale of equity in an associate company. It references compliance with company law, articles of association, and governance rules, and confirms the board's approval and procedural correctness. The document is a formal statement related to board/management decisions rather than a full report, financial statement, or announcement of voting results. It does not contain financial data or detailed management discussion but is a governance-related opinion on a board matter.
2021-04-08 Chinese
安图生物关于取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate from a regulatory authority (Henan Provincial Drug Administration). It details the product name, registration number, validity period, and expected use. The document also discusses the impact of this registration on the company's product line and market competitiveness. There is no financial data, no mention of financial results, no shareholder voting information, no management changes, no legal proceedings, no capital or financing updates, and no reference to any report publication. The document is a regulatory announcement about a product certification, which does not fit into financial report categories but is a regulatory filing. Given the short length (853 characters) and the nature of the content, the best classification is Regulatory Filings (RNS).
2021-03-26 Chinese
安图生物关于全资子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding its wholly-owned subsidiary obtaining a medical device registration certificate. It includes details about the certificate, product specifications, and potential impact on company performance. The document is short (981 characters) and does not contain financial statements or detailed financial data. It is an operational update related to regulatory approval rather than a financial report or management discussion. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a product certification, which aligns best with Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-24 Chinese
安图生物关于取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the receipt of medical device registration certificates for specific products. It includes details about the certificates, product descriptions, R&D investment, and potential impact on the company. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no earnings release, or other report types. The document is a regulatory announcement about product registration, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories.
2021-03-08 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.